This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - Tofacitinib for moderately to severely active ulcerative colitis

Authoring team

NICE guidance states (1):

  • Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment

Tofacitinib (1,2,3):

  • Janus kinases (JAKs) are a group of four intracellular tyrosine kinases mediating the signal transduction of multiple cytokines implicated in several functions including the activation of inflammation
    • JAKS have pivotal role in sustaining chronic inflammation, by stimulating the activity of T and B cells, and the production of mucus and antibodies
    • tofacitinib
      • is an oral small molecule pan-Janus kinase (JAK) inhibitor (molecular weight 312.4 Da; 504.5 for the citrate salt)
      • is the first oral formulation for the treatment of UC (ulcerative colitis)
      • acts on a multitude of cytokines at the same time by inhibiting the JAK/ctivator of transcription (STAT) pathway, resulting in a wider effect on the gastrointestinal inflammation
      • blocks the JAK-1 and JAK-3, and, at high concentrations, tyrosine kinase 2 (TYK2) and JAK-2 pathways
      • the JAKs are the downstream signaling molecules of a large number of the cytokine pathways involved in IBD
        • when a cytokine binds its cell surface receptors, it dimerizes the ligand receptors and this results in phosphorylation of the JAK molecules
        • JAK then activates signal transducer and activator of transcription molecules (STATs), the phosphorylation of which results in STAT migration to the nucleus and activation of gene transcription
        • by targeting JAK signaling, it is possible to affect multiple cytokine pathways thought to be involved in colitis.
      • is rapidly absorbed after oral intake with a time to peak concentration of 1/2 h, thus allowing a more comfortable route of administration for the patient and a quicker effect than the majority of other drugs used in inflammatory bowel disease
      • the short half-life of about 3 h requires twice-a-day intake
      • because it is not a monoclonal antibody, it is not antigenic (2)

Reference:

  • NICE (28 Nov 2018).Tofacitinib for moderately to severely active ulcerative colitis
  • D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631. Published 2019 May 16. doi:10.1177/1756284819848631
  • Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther. 2019;13:4091-4105. Published 2019 Dec 2. doi:10.2147/DDDT.S182891

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.